Epithelial-mesenchymal transition (EMT) is a driving force in tumor progression that transforms relatively benign epithelial tumor cells into mesenchymal or quasi-mesenchymal cells with cancer stem cell (CSC) properties, promoting the malignant phenotype that is highly drug resistant and metastatic. University of Colorado researchers have discovered and optimized lead compounds that reverse EMT. Their data demonstrate that these agents inhibit the tumorigenic and metastatic properties of cancer cells and tumor growth in mice. Furthermore, they have developed innovative mouse models of EMT driven metastasis to advance their drug development program to test in vivo anti-metastatic efficacy and toxicity for the lead compounds.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/cu4873h_ncs.pdf